GENTILINI, PAOLO
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
NA - Nord America 19.113
EU - Europa 10.747
AS - Asia 6.795
SA - Sud America 771
AF - Africa 205
OC - Oceania 167
Continente sconosciuto - Info sul continente non disponibili 50
Totale 37.848
Salva come PNG Salva come JPEG
Nazione #
US - Stati Uniti d'America 18.839
RU - Federazione Russa 3.834
IT - Italia 1.928
SG - Singapore 1.905
CN - Cina 1.341
HK - Hong Kong 1.212
SE - Svezia 1.009
IE - Irlanda 972
PL - Polonia 825
KR - Corea 726
VN - Vietnam 689
BR - Brasile 620
UA - Ucraina 583
DE - Germania 466
FI - Finlandia 347
FR - Francia 309
GB - Regno Unito 251
IN - India 232
JP - Giappone 193
TR - Turchia 163
AU - Australia 162
CA - Canada 158
CH - Svizzera 70
CI - Costa d'Avorio 64
BD - Bangladesh 60
JO - Giordania 57
AR - Argentina 47
IQ - Iraq 40
NL - Olanda 40
NG - Nigeria 38
MX - Messico 36
CO - Colombia 29
EC - Ecuador 29
ES - Italia 26
ID - Indonesia 26
BE - Belgio 25
ZA - Sudafrica 25
MA - Marocco 20
UZ - Uzbekistan 20
JM - Giamaica 19
PK - Pakistan 17
SC - Seychelles 15
AE - Emirati Arabi Uniti 14
CR - Costa Rica 14
VE - Venezuela 14
PH - Filippine 12
KE - Kenya 11
MY - Malesia 11
SA - Arabia Saudita 11
HN - Honduras 10
EG - Egitto 9
LT - Lituania 9
AZ - Azerbaigian 8
DZ - Algeria 8
AT - Austria 7
BG - Bulgaria 7
KG - Kirghizistan 7
PE - Perù 7
PY - Paraguay 7
CZ - Repubblica Ceca 6
LV - Lettonia 6
UY - Uruguay 6
BO - Bolivia 5
CL - Cile 5
OM - Oman 5
PT - Portogallo 5
TN - Tunisia 5
AL - Albania 4
BB - Barbados 4
DO - Repubblica Dominicana 4
EU - Europa 4
GT - Guatemala 4
LB - Libano 4
NI - Nicaragua 4
NZ - Nuova Zelanda 4
PA - Panama 4
PR - Porto Rico 4
SV - El Salvador 4
TH - Thailandia 4
TT - Trinidad e Tobago 4
BY - Bielorussia 3
CY - Cipro 3
GR - Grecia 3
IL - Israele 3
IR - Iran 3
KZ - Kazakistan 3
NP - Nepal 3
PS - Palestinian Territory 3
AM - Armenia 2
BH - Bahrain 2
ET - Etiopia 2
GY - Guiana 2
HU - Ungheria 2
LA - Repubblica Popolare Democratica del Laos 2
LK - Sri Lanka 2
MN - Mongolia 2
MU - Mauritius 2
QA - Qatar 2
RO - Romania 2
SN - Senegal 2
Totale 37.776
Salva come PNG Salva come JPEG
Città #
Santa Clara 3.776
Singapore 1.251
Fairfield 1.223
Ashburn 1.216
San Jose 1.095
Chandler 1.077
Hong Kong 974
Dublin 971
Jacksonville 914
Warsaw 815
Seoul 721
Woodbridge 594
Cambridge 563
Seattle 550
Milan 492
Wilmington 452
Houston 449
Beijing 388
Los Angeles 371
The Dalles 333
Buffalo 315
Council Bluffs 280
Princeton 262
Ann Arbor 250
Ho Chi Minh City 215
Lauterbourg 209
Boardman 206
Boston 201
Dallas 193
Tokyo 192
Rome 178
Hanoi 163
Melbourne 163
Hefei 160
Mumbai 139
Medford 122
Lawrence 118
Altamura 114
Izmir 107
Moscow 92
New York 82
Munich 78
San Diego 73
Bern 68
Norwalk 67
Phoenix 67
Abidjan 64
Columbus 62
Shanghai 61
Naples 60
Florence 59
Paris 51
Kent 50
Turin 48
Dearborn 47
Helsinki 45
São Paulo 43
Redondo Beach 40
Bologna 38
Toronto 38
Abuja 37
Turku 37
London 36
Orem 34
Da Nang 33
Andover 32
Chicago 31
Hillsboro 31
Falls Church 30
Verona 30
Palermo 28
Auburn Hills 27
Guangzhou 27
Bremen 25
Brussels 25
Frankfurt am Main 25
Frankfurt Am Main 24
Haiphong 24
Montreal 24
West Jordan 24
Chennai 23
Bari 22
Brooklyn 22
Washington 21
San Francisco 20
Manchester 19
Tashkent 19
Baghdad 18
Figino 18
Genoa 17
Salerno 17
Belo Horizonte 16
Philadelphia 16
Stockholm 16
Atlanta 15
Dhaka 15
Yubileyny 15
Denver 14
Rio de Janeiro 14
Brescia 13
Totale 23.979
Salva come PNG Salva come JPEG
Nome #
Serum hepatitis delta virus RNA in patients with delta hepatitis and in liver graft recipients 1.206
Antifibrogenic effects of canrenone, an antialdosteronic drug, on human hepatic stellate cells 349
Nitrovasodilators inhibit platelet-derived growth factor-induced proliferation and migration of activated human hepatic stellate cells. 323
Differential expression of two isoforms of the chemokine receptor CXCR3 determines the ultimate effect of IP-10 on survival of human hepatic stellate cells (HSC) 323
Inhibition by pentoxifylline of extracellular signal-regulated kinase activation by platelet-derived growth factor in hepatic stellate cells 307
The mitogenic effect of platelet-derived growth factor in human hepatic stellate cells requires calcium influx 301
Fat-storing cells as liver-specific pericytes: spatial dynamic of agonist-stimulated intracellular calcium transients. 274
The kinin system and other vasoactive substances in chronic liver disease. 245
[Renal function in chronic hepatopathies] 242
[Some aspects of the physiopathology of renal insufficiency in the course of chronic liver diseases] 237
Amplification of hepatitis delta virus RNA sequences by polymerase chain reaction: a tool for viral detection and cloning 231
Effect of antiviral treatment in patients with chronic HCV infection and t(14;18) translocation 226
SURVIVAL AND PROGNOSTIC FACTORS IN PATIENTS WITH HEPATOCELLULAR CARCINOMA TREATED BY PERCUTANEOUS ETHANOL INJECTION: A 10-YEAR EXPERIENCE. 226
Reduced platelet thromboxane A2 production as a possible cause of defective platelet aggregation in cirrhosis. 223
Thrombopoietin stimulates migration and activates multiple signaling pathways in hepatoblastoma cells. 222
Differential requirement of members of the MAPK family for CCL2 expression by hepatic stellate cells 213
Altered cardiovascular responsiveness to active tilting in nonalcoholic cirrhosis. 212
Bile acid inhibition of p-glycoprotein mediated transport in multidrug resistant cells and rat liver canalicular membrane vesicles 206
Plasma levels of brain natriuretic peptide in patients with cirrhosis. 203
Ascites and hepatorenal syndrome during cirrhosis: two entities or the continuation of the same complication? 199
THROMBOPOIETIN STIMULATES MIGRATION AND INVASION OF HepG2 CELLS. 199
Renal hemodynamic and natriuretic effects of human atrial natriuretic factor infusion in cirrhosis with ascites. 197
Altered platelet function in cirrhosis of the liver: impairment of inositol lipid and arachidonic acid metabolism in response to agonists 196
Combined presence of HCVRNA sequences and t(14;18) (q32;q21) translocation in PBMC from patients with chronic HCV infection 195
Expression of IP-10 and its receptor CXCR3 in hepatic stellate cells identifies a novel autocrine and paracrine system. 195
Analysis of HCV persistence in patients with sustained virological response 194
EFFECTS OF NITRIC OXIDE (NO)-DONORS ON ACTIVATED HUMAN HEPATIC STELLATE CELLS (HSC): CELLULAR BASIS FOR THE TREATMENT OF PORTAL HYPERTENSION. 194
Altered furosemide pharmacokinetics in chronic alcoholic liver disease with ascites contributes to diuretic resistance 194
CD81 Modulation by Immobilized Monoclonal Antibodies is Able to Promote B-cell proliferation and C-MYC expression 194
Albumin improves the response to diuretics in patients with cirrhosis and ascites: results of a randomized, controlled trial. 193
Hepatocellular carcinoma in mixed cryoglobulinemia patients 192
Ascites and hepatorenal syndrome 192
Increased production of nitric oxide by neutrophils and monocytes from cirrhotic patients with ascites and hyperdynamic circulation. 192
Expression and function of integrin receptors for collagen and laminin in cultured human hepatic stellate cells. 191
Defective aggregation in cirrhosis is independent of in vivo platelet activation. 191
Long-term albumin infusion improves survival in patients with cirrhosis and ascites: an unblinded randomized trial. 190
Functional insufficiency in chronic liver disease patients. The hepatorenal syndrome 189
Systemic hemodynamics and renal function in cirrhotic patients during plasma volume expansion. 188
Cardiovascular effects of canrenone in patients with preascitic cirrhosis 188
Cardiac and renal response to posture in cirrhotics with and without essential hypertension 187
Infection of peripheral mononuclear blood cells by hepatitis C virus 185
ALBUMIN IMPROVES RESPONSE TO DIURETICS IN DECOMPENSATED CIRRHOTIC PATIENTS. 185
Expression of the thrombin receptor in human liver: up-regulation during acute and chronic injury. 184
Albumin improves the response to diuretics in patients with cirrhosis and ascites: results of a randomized, controlled trial 182
CD81 modulation by immobilized monoclonal antibodies is able to promote B-cell proliferation and c-myc expression 179
Expression of platelet-derived growth factor in a model of acute liver injury. 178
Loop diuretic therapy in liver cirrhosis with ascites 177
CD81 MODULATION BY IMMOBILIZED MONOCLONAL ANTIBODIES IS ABLE TO PROMOTE B-CELL PROLIFERATION AND C-MYC EXPRESSION 177
Ascites and hepatorenal syndrome during cirrhosis: two entities or the continuation of the same complication? 175
Evidence for a storage pool defect in platelets from cirrhotic patients with defective aggregation 174
CARDIOVASCULAR EFFECTS OF CANRENONE IN PRE-ASCITIC CIRRHOSIS. 174
Pharmacokinetics and pharmacodynamics of torasemide and furosemide in patients with diuretic resistant ascites. 173
Cross-talk between phosphatidylinositol 3-kinase (PI3-K) and the NA+/H+ exchanger in hepatic stellate cells (HSC): effect of canrenone. 172
Effect of alpha-interferon on hepatitis C virus chronic infection in mixed cryoglobulinemia patients 171
Fibrogenesi epatica: valutazione dell'espressione genica di citochine fibrogeniche e dei tipi più rappresentanti di collagene. 171
Biosynthesis of platelet-activating factor and its 1O-acyl analogue by liver fat-storing cells. 171
HCV INFECTION OF PERIPHERAL AND LIVER MONONUCLEAR-CELLS - PATHOGENIC IMPLICATIONS 171
Blunted natriuretic response to low-dose brain natriuretic peptide infusion in nonazotemic cirrhotic patients with ascites and avid sodium retention. 170
Hepatitis C virus as a lymphotropic agent: evidence and pathogenetic implications 169
T(14;18) translocation in chronic hepatitis C virus infection 168
Alterazioni del sistema pPAF-AH/PAF in pazienti con infezione cronica da HCV 168
Cardiovascular and renal function in normotensive and hypertensive patients with compensated cirrhosis: effects of posture. 167
Amplification of HDV RNA sequences by polymerase chain reaction (PCR). 166
Altered renal and platelet arachidonic acid metabolism in cirrhosis. 164
Thromboxane-receptor blockade increases water diuresis in cirrhotic patients with ascites. 163
Cardiovascular and renal function in normotensive and hypertensive patients with compensated cirrhosis: effects of posture. 163
Defective signal transduction in platelets from cirrhotic patients is associated with increased cyclic AMP and cyclic GMP content. 162
Patterns and mechanisms of hepatitis B/hepatitis D reinfection after liver transplantation 162
Pathogenesis and treatment of ascites in hepatic cirrhosis. 162
Torasemide in the treatment of patients with cirrhosis and ascites. 161
Applicazione della metodica PCR (polymerase chain reaction) ed altre tecniche di biologia molecolare allo studio dell'infezione da virus C dell'epatite. 161
Hepatitis C virus infection in mixed cryoglobulinemia and B-cell non-Hodgkin's lymphoma: evidence for a pathogenetic role 159
Effects of repeated atrial natriuretic peptide bolus injections in cirrhotic patients with refractory ascites. 157
Multiple biological effects of endothelin-1 in fat-storing cells isolated from human liver. 156
Crioglobulinemia e linfoma in corso di infezione da HCV 156
Up-regulated expression of fractalkine and its receptor CX3CR1 during liver injury in humans 156
Respiratory mechanics in patients with tense cirrhotic ascites. 156
Long-term clinical and virological outcome after liver transplantation for cirrhosis caused by chronic delta hepatitis 155
Chemotherapy of primary and secondary liver cancer: is it useful? 155
Hepatic lipid peroxidation and aldehyde dehydrogenase activity in alcoholic and non alcoholic liver disease. 155
HCV infection in mixed cryoglobulinemia and B-cell non-Hodgkin’s lymphoma. 155
Transforming growth factor beta1 regulates platelet derived growth factor receptor beta subunit in human liver fat storing cells 153
Purification of PGE2 in the urine of cirrhotic patients: comparison of three chromatographic techniques. 153
Efficacia del trattamento antivirale nell’indurre la regressione di cloni B cellulari alberganti la traslocazione t(14;18) nell’infezione cronica da virus C dell’epatite (HCV). 153
Organization of the lymphoid tissue in livers with chronic active hepatitis. 153
Update on ascites and hepatorenal syndrome 153
Hemodynamic, renal, and endocrine effects of acute inhibition of nitric oxide synthase in compensated cirrhosis 152
Effects of low-dose captopril on renal hemodynamics and function in patients with cirrhosis of the liver. 152
Monocyte chemotactic protein-1 as a chemoattractant for human hepatic stellate cells. 152
Relevance of inapparent coinfection by hepatitis B virus in alpha interferon-treated patients with hepatitis C virus chronic hepatitis 152
Bcl-2 rearranged B cell clones in chronic HCV infection: a possible factor negatively influencing the virological response to treatment 152
Changes in the production of nitric oxide and superoxide by inflammatory cells in liver cirrhosis. 152
Integrin-mediated stimulation of monocyte chemotactic protein-1 expression. 151
Impaired superoxide anion, platelet-activating factor, and leukotriene B4synthesis by neutrophils in cirrhosis. 151
The cellular and molecular basis of liver fibrogenesis. 150
[Viral liver cirrhosis: natural course, pathogenesis and clinical implications of the complications] 149
[Determination of prostaglandin E2 and F2 alpha in the urine of cirrhotic patients: comparison of 3 different chromatographic methods] 149
Infection of peripheral blood mononuclear cells by hepatitis C virus in mixed cryoglobulinemia 148
Uveitis in autoimmune hepatitis: a case report. 148
Effect of potassium canrenoate, an anti-aldosterone agent, on incidence of ascites and variceal progression in cirrhosis 148
Totale 19.555
Salva come PNG Salva come JPEG
Categoria #
all - tutte 99.537
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 99.537
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2021/20221.344 0 0 46 71 42 51 49 80 66 42 374 523
2022/20234.160 425 423 198 318 430 836 569 248 467 28 119 99
2023/20241.241 64 179 277 76 77 144 35 258 22 31 40 38
2024/202510.312 304 1.093 730 1.569 3.508 1.078 94 613 538 210 316 259
2025/202610.322 1.313 1.432 716 926 1.063 324 1.151 412 871 515 161 1.438
2026/20271.178 257 419 502 0 0 0 0 0 0 0 0 0
Totale 37.848